New Treatment Regimen for Drug-Resistant TB UPSC

India will introduce the BPaL (Bedaquiline, Pretomanid, and Linezolid) regimen for all multi/extensively drug-resistant tuberculosis (M/XDR-TB) patients. Mycobacterium Tuberculosis, the microorganism that causes tuberculosis (TB) can develop resistance to the antimicrobial tablets used to remedy the disorder. Multidrug-resistant TB (MDR-TB) is TB that doesn’t respond to at least isoniazid and rifampicin, the 2 most powerful anti-TB drugs.